4//SEC Filing
Rovaldi Christopher 4
Accession 0001209191-22-023860
CIK 0001664710other
Filed
Apr 7, 8:00 PM ET
Accepted
Apr 8, 4:21 PM ET
Size
8.9 KB
Accession
0001209191-22-023860
Insider Transaction Report
Form 4
Rovaldi Christopher
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2022-04-06$16.00/sh+1,728$27,648→ 1,728 total - Sale
Common Stock
2022-04-06$65.00/sh−1,728$112,320→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-06−1,728→ 8,002 totalExercise: $16.00Exp: 2030-04-07→ Common Stock (1,728 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001706040
Filing Metadata
- Form type
- 4
- Filed
- Apr 7, 8:00 PM ET
- Accepted
- Apr 8, 4:21 PM ET
- Size
- 8.9 KB